Advertisement

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C. Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E. G. Havenith, Simon Chivers, Francois D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley and Patrick H. van Berkel

Article Information

Citation 
vol. 131 no. 10 1094-1105
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted October 26, 2017
  • Accepted December 21, 2017
  • Published online March 8, 2018.

Article Versions


Contributors 
  • Francesca Zammarchi, 1ADC Therapeutics (UK) Limited, London, United Kingdom;
  • Simon Corbett, 2Spirogen/Medimmune Ltd, London, United Kingdom; and 3Cancer Research UK Drug DNA Interactions Research Group and
  • Lauren Adams, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • Peter C. Tyrer, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • Konstantinos Kiakos, 3Cancer Research UK Drug DNA Interactions Research Group and
  • Narinder Janghra, 4Department of Pathology, University College London Cancer Institute, London, United Kingdom
  • Teresa Marafioti, 4Department of Pathology, University College London Cancer Institute, London, United Kingdom
  • Charles E. Britten, 1ADC Therapeutics (UK) Limited, London, United Kingdom;
  • Carin E. G. Havenith, 1ADC Therapeutics (UK) Limited, London, United Kingdom;
  • Simon Chivers, 1ADC Therapeutics (UK) Limited, London, United Kingdom;
  • Francois D’Hooge, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • David G. Williams, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • Arnaud Tiberghien, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • Philip W. Howard, 2Spirogen/Medimmune Ltd, London, United Kingdom; and
  • John A. Hartley, 1ADC Therapeutics (UK) Limited, London, United Kingdom; 2Spirogen/Medimmune Ltd, London, United Kingdom; and 3Cancer Research UK Drug DNA Interactions Research Group and
  • Patrick H. van Berkel, 1ADC Therapeutics (UK) Limited, London, United Kingdom;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output